Mineralocorticoid receptor antagonist pre-treatment and early post-treatment to minimize reperfusion injury after ST-elevation myocardial infarction: The MINIMIZE STEMI trial

Heerajnarain Bulluck, Georg M. Fröhlich, Jennifer M. Nicholas, Shah Mohdnazri, Reto Gamma, John Davies, Alex Sirker, Anthony Mathur, Daniel Blackman, Pankaj Garg, James C. Moon, John P. Greenwood, Derek J. Hausenloy

Research output: Contribution to journalArticlepeer-review

17 Citations (Scopus)
4 Downloads (Pure)


Mineralocorticoid receptor antagonist (MRA) therapy has been shown to prevent adverse left ventricular (LV) remodeling in ST-segment elevation myocardial infarction (STEMI) patients with heart failure. Whether initiating MRA therapy prior to primary percutaneous coronary intervention (PPCI) accrues additional benefit of reducing myocardial infarct size and preventing adverse LV remodeling is not known. We aimed to investigate whether MRA therapy initiated prior to reperfusion reduces myocardial infarct (MI) size and prevents adverse LV remodeling in STEMI patients.
Original languageEnglish
Pages (from-to)60-67
Number of pages8
JournalAmerican Heart Journal
Early online date20 Feb 2019
Publication statusPublished - 1 May 2019

Cite this